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Abstract
The marine transaminase, P-ω-TA, can be employed for the transamination from 1-aminotetralins and 
1-aminoindanes with differentiation of stereochemistry at both the site of reaction and at a remote 
stereocentre resulting in formation of ketone products with up to 93% ee. While 4-substituents are 
tolerated on the tetralin core, the presence of 3- or 8- substituents are not tolerated by the 
transaminase. In general P-ω-TA shows capacity for remote diastereoselectivity, although both the 
stereoselectivity and efficiency is dependent on the specific substrate structure. Optimum efficiency 
and selectivity are seen with 4-haloaryl-1-aminotetralins and 3-haloaryl-1-aminoindanes, which may 
be associated with the marine origin of this enzyme.


















































































Chiral amines and related derivatives are common features found in many natural products (e.g. 
alkaloids), and the prevalence of similar motifs in pharmaceuticals and fine chemicals makes the 
availability of enantiopure amines as building blocks critically important to the pharmaceutical 
industry.1, 2 For example, the aminotetralin motif (Figure 1) is present in a variety of pharmaceuticals, 
such as the anti-depressants sertraline and norsertraline with an α-aminotetralin core, and rotigotine, 
a treatment for Parkinson’s disease containing a β-aminotetralin core unit (Figure 1).
Figure 1: Examples of pharmaceuticals with an α- or β-aminotetralin core
To develop strategies for the enantioselective synthesis of complex amine building blocks, in addition 
to controlling the stereochemistry at the amine site, control of the stereochemistry at additional 
stereocentres in the molecule must also be addressed, and frequently this is more challenging. For 
example, in the synthesis of sertraline, further to controlling the stereochemistry at C-1 bearing the 
amino-substituent, the absolute stereochemistry at C-4 must also be controlled in the overall synthetic 
pathway. 
The exquisite chemo-, regio- and stereoselectivity of biocatalysts can open the door to effective 
synthetic routes to enantiopure compounds, and in addition the use of biocatalysis often has positive 
benefits in relation to the environmental impact of a process, satisfying 10 of the 12 principles of green 
chemistry.3 From a synthetic perspective transaminases can provide a route to enantiopure amines, 
via asymmetric transamination of ketones, or alternatively via kinetic resolution in deamination of 
racemic amines.4 In the last decade transaminases have attracted considerable attention in synthetic 
biocatalysis, providing access to enantiopure amines in a synthetically versatile manner, and 
numerous reports have described their use for API synthesis in the pharmaceutical industry.5-13 An 










R1 = NH2, R2 = H
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of an evolved and then immobilised transaminase for the synthesis of the API Sitagliptin (Januvia®), a 
Merck drug used in the treatment of diabetes mellitus type 2. This biocatalytic transformation 
surpasses its chemocatalytic counterpart in terms of selectivity, toxicity and efficiency.14, 15
While biocatalysis offers many advantages in enantioselective synthesis, in general, the focus is usually 
on the control of the absolute stereochemistry at, or near, the site of reaction. Resolution of a remote 
stereocentre is relatively unusual; however, as an example, the use of hydrolases to mediate the 
kinetic resolution of a remote stereocentre has been previously reported.16-22 However in almost all 
the reports of the use of transaminases the focus is on controlling the absolute stereochemistry at the 
amine site,8, 23, 24 with just a small number of reports of the resolution of an α-stereocentre using 
transaminases (e.g. Figure 2).25, 26
Figure 2: Examples of transaminase mediated asymmetric transamination of a compound with an α-stereocentre25, 26
The marine environment has provided a wealth of diversity in natural products, bioactive compounds 
and biocatalysts; developments in (meta)genomic-based technologies, that capture and decode the 
genetic blueprint of oceanic organisms, without the need to grow or sustain the source organism, have 
proven a vital tool in marine biodiscovery.27-31 In the context of synthetic chemistry enzymes extracted 
from the marine environment often display a much higher tolerance when exposed to diverse 
substrates and reaction media, pressure and heat  in comparison to their terrestrial counterparts.32-34
In the first example of transaminase-mediated resolution of a remote stereocentre, we recently 
reported a marine ω-transaminase P-ω-TA, from a Pseudovibrio species isolated from a marine 
sponge, identified using genome mining techniques.35 P-ω-TA was used effectively for the resolution 
of amine 1a, a potential intermediate in the synthesis of sertraline. Comparing the marine 
transaminase to the control transaminase Chromobacterium violaceum (Cv-ω-TA)36 we showed that 






































































































the trans-1a enantiomer (Table 1), unlike Cv-ω-TA which similarly processed both cis- and trans-1a, 
without noticeable discrimination. To the best of our knowledge, this was the first report of remote 
stereoselection using an ω-transaminase.35











-TA, PLP (1 mM)
sodium pyruvate (1 eq.),
sodium phosphate buffer,
pH 8.5, 10% v/v DMSO,
















P-ω-TA 54 52 >99 93 (4S)











-TA, PLP (1 mM)
sodium pyruvate (1 eq.),
sodium phosphate buffer,
pH 8.5, 10% v/v DMSO,














P-ω-TA 5 -1 2 5 (4R)
Cv-ω-TA 44 54 95 80 (4R)
1 Conversion too low to calculate
Herein, given the synthetic advantage associated with the remote stereoselection of P-ω-TA, we 
explore the expansion of the substrate scope beyond 1a to determine the tolerance of P-ω-TA to 

















































































structural changes within the general framework of the sertraline intermediate 1a, and to specifically 
explore the influence of variation of the substrate structure on efficiency, enantioselectivity and 
remote stereoselection. The overall objective was to establish the synthetic potential of P-ω-TA for 
enantioselective transformation with stereocontrol at the site of reaction in addition to distinguishing 
the stereochemistry at a remote stereocentre. 
Results & Discussion
Substrates were designed to explore both steric and electronic effects of substituents on the tetralin 
core, the impact of ring size and the influence of different aryl and alkyl-substituents in the 3- and 4-














Changing ring size - 5-, 6-,
7-membered rings better?
Examining substituents - aryl






Scheme 1: Amine substrates investigated
Substrate synthesis 
Racemic samples of each of the cis- and trans-amines were synthesised in addition to the racemic 
ketones as standards for chiral HPLC method development. The known ketones 2b-2m were 
synthesised following literature procedures (details in the Supporting Information).38-46 Subsequent 
transformation of each ketone 2b-2m to both diastereomeric amines was undertaken as summarised 
below in Schemes 2–5, following literature precedent. While amines cis-1e,47 1h,48 1j49 and 1l49 are 
known compounds with spectroscopic characteristics in agreement with literature data, amines 1b, 
1c, 1d, trans-1e 1f, 1g, 1k and 1m are novel and were fully characterised in this work. The 
hydrochloride salt of cis- and trans-1i has been reported before with only mass spectrometry 
reported.50 Similarly, the intermediate alcohols 6b and 6c, azides 7b, 7c, 7e, cis-7f, trans-7h, trans-7i 
and trans-7k, and Boc protected amines 8d and 8m are novel and were fully characterised in this work; 
other intermediates were known, with spectroscopic characteristics in agreement with reported data.

















































































For the synthesis of each diastereomeric amine 1b, 1c, 1e and 1j, the corresponding ketone was 
reduced using sodium borohydride following a general procedure,35, 51 to give a mixture of 
diastereomeric alcohols, which were separable by careful chromatography. The reductions generally 
proceeded cleanly with full conversion; however, in practice, the isolated yields of pure diastereomers 
was determined by the challenging chromatographic separation of the diastereomers. Each of the 
diastereomerically pure alcohols 6b, 6c, 6e, 6j were converted to their corresponding azides 7b, 7c, 
7e, 7j with clean inversion of stereochemistry using diphenylphosphoryl azide and 1,8-









2b: n=1, x=H, R=5-,8-CH3
2c: n=1, x=H, R=7-CH3
2e: n=1, x=H, R=H
2j: n=0, x=Cl, R=H
cis- 6b, 6c, 6e, 6j





























trans- 7b, 7c, 7e, 7j
cis- 7b, 7c, 7e, 7j
trans- 1b, 1c, 1e,1j



















Scheme 2: Synthesis of cis- and trans-1b, 1c, 1e, 1j from the corresponding ketones via reduction, azidation with inversion of 
stereochemistry and subsequent azide reduction
Where the initial sodium borohydride reduction of the ketone afforded primarily one diastereomer 
and the separation/purification of the minor diastereomer proved difficult, the major diastereomer 
(trans for 1f and cis for 1h, 1i, 1k and 1l ) was subjected to azidation and reduction conditions to 
synthesise the inverted amine (cis-1f and trans-1h, 1i, 1k and 1l, Scheme 3) by the same method as in 
Scheme 2.52 The opposite diastereomers could be obtained by direct reductive amination of the 
ketone through treatment with ammonia in methanol and titanium(IV) isopropoxide or titanium(IV) 
ethoxide, followed by in-situ sodium borohydride reduction furnishing primarily the trans-amine 1f 
and cis-amine 1h, 1i, 1k and 1l (Scheme 3).35, 43 In general the crude amine was converted to the HCl 
salt, washed, precipitated, recrystallized if necessary and then a salt break furnished the pure amine 
without column chromatography. 


































































































trans 1f: n=1, R1=H, R2=CH2Ph
cis 1h: n=1, R1=Ph, R2=H
cis 1i: n=0, R1=H, R2=Ph
cis 1k: n=0, R1=H, R2=4-F-Ph











1) Ti(iPrO)4 or Ti(EtO)4,
NH3, MeOH, rt, 18h
2) NaBH4, rt, 3–5h R
1
trans-6f: n=1, R1=H, R2=CH2Ph
cis 6h: n=1, R1=Ph, R2=H
cis 6i: n=0, R1=H, R2=Ph
cis 6k: n=0, R1=H, R2=4-F-Ph
cis 6l: n=0, R1=H, R2=CH3
cis 7f: n=1, R1=H, R2=CH2Ph
trans 7h: n=1, R1=Ph, R2=H
trans 7i: n=0, R1=H, R2=Ph
trans 7k: n=0, R1=H, R2=4-F-Ph
trans 7l: n=0, R1=H, R2=CH3
cis 1f: n=1, R1=H, R2=CH2Ph
trans 1h: n=1, R1=Ph, R2=H
trans 1i: n=0, R1=H, R2=Ph
trans 1k: n=0, R1=H, R2=4-F-Ph
trans 1l: n=0, R1=H, R2=CH3
R1 R1 R1
Scheme 3: Synthesis of amines via direct reductive amination or via reduction, azidation and azide reduction.
Reduction of the 4-methyl-1-tetralone 2g substrate furnished a mixture of cis- and trans-1g alcohols 
in a diastereomeric ratio of 55:45 respectively, which could not be separated through flash column 
chromatography.51 However, the cis-alcohol 6g could be obtained through recrystallization from 
hexane. The trans-alcohol 6g was accessed by inversion of the stereochemistry via an ester 
intermediate following a literature procedure.53 The two novel amines cis- and trans-1g were each 
obtained by azidation and reduction as described above with clean inversion in each case (Scheme 
4).52 
1) DPPA, DBU,






2) LiAlH4, THF, rt, 16h
or







toluene, 0 °C–rt, 16h
NH2
2) LiAlH4, THF, rt, 16h
or
PPh3, H2O, THF, 16h cis 1g
2g
Scheme 4: Synthesis of cis- and trans- aminotetralin 1g
When the synthesis of amines 1d (p-OMe) and novel 1m (7-membered ring) was attempted following 
the synthetic sequence outlined in Scheme 2, the corresponding amines were not isolated as single 
diastereomers. To overcome this problem, the ketones 2d and 2m were subjected instead to reductive 

















































































amination and the diastereomeric amines in the crude mixtures were protected using Boc-anhydride 
(Scheme 5).54 The Boc amines 8d and 8m were purified and the diastereomers separated by flash 
column chromatography on silica gel. The rather low yields can again be attributed to the challenging 
separation. In addition to making the compounds easier to separate, this approach had the advantage 
that the Boc protected amines could be used for HPLC method development. The free amines 1d and 
1m were readily accessed by deprotection of the Boc amines under acidic conditions. Characterisation 
of the benzosuberone derived amines 1m and Boc amines 8m is complicated by conformational 
effects in the 1H and 13C NMR spectra.55
O
n
1) i) Ti(EtO)4, NH3,
MeOH, rt, 18h


















trans- 8d or 8m
cis- 1d or 1m
trans- 1d or 1m
HCl, dioxane, rt
HCl, dioxane, rt
Scheme 5 – Reductive amination of ketone 2d and 2m with diastereomer separation of the N-Boc derivatives to yield 
diastereomerically pure amines 1d and 1m
Substrate scope 
As our primary objective was to establish a substrate scope for the remote stereoselection, we tested 
a range of substrates against the biocatalysts P-ω-TA and the control Cv-ω-TA for activity in the 
thermodynamically favoured deamination reaction using the cis- and trans-amine substrates 
separately (Table 2 and Table 3 respectively). All the biotransformations reported in Tables 2 and 3 
below were conducted under the same conditions to enable comparison and insight into the impact 
of substituents. For each substrate, optimisation of the efficiency and stereoselectivity by adjusting 
the reaction conditions (e.g. the reaction time, scale up, etc) could be envisaged. The efficiencies of 
conversion are recorded in Tables 2 and 3 below in two ways, firstly based on integration of 1H NMR 
spectra of the crude product mixtures, and secondly by use of Ecalc based on the chiral HPLC data.37 
While in most instances there is reasonable alignment, differences may be explained by the challenges 

















































































in accurately integrating NMR spectra where one of the components is present in a very low level, e.g. 
Table 2, entry 16 in which case Ecalc perhaps is a better indicator of biocatalyst efficiency.




























































































whole cells expressing -TA,
sodium pyruvate (1 eq.),
PLP (1 mM)
sodium phosphate buffer, pH 8.5,
10% v/v DMSO,

































cis-1b R3, R6 = CH3, R4, R5 = H
cis-1c R3, R4, R6 = H, R5 = CH3
cis-1d R3, R5, R6 = H, R4 = OMe
cis-1e R1 = H, R2 = Ph
cis-1f R1 = H, R2 = CH2Ph
cis-1g R1 = H, R2 = Me








cis-1i R2 = Ph
cis-1j R2 = 3,4-Cl-Ph
cis-1k R2 = 4-F-Ph














Conversion (%) ee %Entry Substrate TA
1H NMR Ecalc37 eeS eeP
E37
1 cis-1b P-ω-TA 0 - - - -
2 cis-1b Cv-ω-TA 6 3 1 33 2
3 cis-1c P-ω-TA 7 6 5 82 10
4 cis-1c Cv-ω-TA 50 51 >99 94 170
5 cis-1d P-ω-TA 28 31 42 93 42
6 cis-1d Cv-ω-TA 51 55 >99 82 52
7 cis-1e P-ω-TA -1 8 8 93 30
8 cis-1e Cv-ω-TA -1 16 11 56 4
9 cis-1f P-ω-TA 4 12 7 50 3
10 cis-1f Cv-ω-TA 61 60 >99 65 23
11 cis-1g P-ω-TA 14 16 18 93 33
12 cis-1g Cv-ω-TA 53 55 >99 82 52
13 cis-1h P-ω-TA 0 - - - -
14 cis-1h Cv-ω-TA 0 - - - -
15 cis-1i P-ω-TA 4 14 7 43 3
16 cis-1i Cv-ω-TA 100 71 10 4 1
17 cis-1j P-ω-TA 46 45 72 87 31
18 cis-1j Cv-ω-TA 51 52 82 77 19
19 cis-1k P-ω-TA 51 51 84 82 27
20 cis-1k Cv-ω-TA 76 78 >99 28 7
21 cis-1l P-ω-TA 63 42 57 79 3
22 cis-1l Cv-ω-TA 96 89 88 11 15
23 cis-1m P-ω-TA 27 17 20 95 47
24 cis-1m Cv-ω-TA 53 49 93 96 168
1 It was not possible to accurately estimate the % conversion using 1H NMR spectroscopy.




























































































whole cells expressing -TA,
sodium pyruvate (1 eq.),
PLP (1 mM)
sodium phosphate buffer, pH 8.5,
10% v/v DMSO,























trans-1b R3, R6 = CH3, R4, R5 = H
trans-1c R3, R4, R6 = H, R5 = CH3
trans-1d R3, R5, R6 = H, R4 = OMe
trans-1e R1 = H, R2 = Ph
trans-1f R1 = H, R2 = CH2Ph
trans-1g R1 = H, R2 = Me








trans-1i R2 = Ph
trans-1j R2 = 3,4-Cl-Ph
trans-1k R2 = 4-F-Ph























Conversion (%) ee %Entry Substrate TA
1H NMR Ecalc37 eeS eeP
E37
1 trans-1b P-ω-TA 0 - - - -
2 trans-1b Cv-ω-TA 0 - - - -
3 trans-1c P-ω-TA 0 - - - -
41 trans-1c Cv-ω-TA 10 - - - -
51 trans-1d P-ω-TA <7 - - - -
6 trans-1d Cv-ω-TA 52 54 94 82 36
7 trans-1e P-ω-TA 0 - - -
8 trans-1e Cv-ω-TA -2 22 24 87 18
9 trans-1f P-ω-TA 0 - - - -
10 trans-1f Cv-ω-TA 53 54 >99 84 60
11 trans-1g P-ω-TA 18 20 23 94 40
12 trans-1g Cv-ω-TA 51 53 >99 89 90
13 trans-1h P-ω-TA 0 - - - -
14 trans-1h Cv-ω-TA 0 - - - -
15 trans-1i P-ω-TA <2 3 1 28 2
16 trans-1i Cv-ω-TA <2 2 1 63 4
17 trans-1j P-ω-TA 4 6 1 16 1
18 trans-1j Cv-ω-TA 8 11 7 58 4
19 trans-1k P-ω-TA 0 - - - -
20 trans-1k Cv-ω-TA 4 6 4 62 4
21 trans-1l P-ω-TA <2 5 3 61 4
22 trans-1l Cv-ω-TA 29 30 32 76 10
23 trans-1m P-ω-TA 0 - - - -
24 trans-1m Cv-ω-TA 49 - - 92 -
1 It was not possible to estimate enantiopurity accurately from the HPLC data due to the limited extent of conversion.
2 It was not possible to accurately estimate the % conversion using 1H NMR spectroscopy.

















































































Substrates 1b–d illustrate the effects of substituents on the benzene ring of the tetralin core. 
 cis- and trans-1b (Table 2 and Table 3, entries 1&2 respectively)
Examining the outcome of the reactions of cis- and trans-1b, with methyl groups in the 5- and 
8-positions, it is clear that the increased steric demand close to the site of reaction completely shuts 
down any enzyme activity towards cis- and trans-1b (Table 2 and Table 3, entries 1&2 respectively).
 cis- and trans-1c (Table 2 and Table 3, entries 3&4 respectively)
With a methyl substituent at the 7-position on the aromatic ring of the tetralin core, the kinetic 
resolution of cis-1c using P-ω-TA (Table 2, entry 3) displayed diminished activity when compared to 
the conversion observed for cis-1a, the control Cv-ω-TA showed high activity (50% conversion) and 
enantioselectivity [>99% enantiomeric excess of the product (eep)] against cis-1c (Table 2, entry 4). 
Interestingly, in contrast to the conversion of trans-1a, in this case the control enzyme Cv-ω-TA did 
not react to any significant extent with trans-1c (Table 3, entry 4). 
 cis- and trans-1d (Table 2 and Table 3, entries 5&6 respectively)
To investigate the effect of electron-donating groups on the activity of the novel transaminase, a 
substrate with a methoxy group in the 6-position 1d was synthesised. The P-ω-TA mediated kinetic 
resolution of cis-1d (Table 2, entry 5) led to a slightly reduced activity and decreased selectivity, while 
the activity of Cv-ω-TA (Table 2, entry 6) was unaffected by the presence of the 6-methoxy substituent 
when compared to cis-1a (Table 1). The activity and selectivity of the known control Cv-ω-TA towards 
trans-1d (Table 3 entry 6) was comparable to that observed for cis-1d, but for P-ω-TA the activity for 
trans-substituted substrate 1d (Table 3, entry 5) was much lower than cis-1d.
Substrates 1e–h illustrates the effects of substituents at the remote stereocentre of the tetralin core. 
 cis- and trans-1e (Table 2 and table 3, entries 7&8 respectively)
In contrast to 1a, use of the unsubstituted C4 phenyl substituent in 1e has an impact on the activity 
and stereochemical outcome using both transaminases. Focusing initially on Cv-ω-TA it is clear that 
once again both the cis (Table 2, entry 8) and trans (Table 3, entry 8) isomers are processed with similar 
efficiencies but with decreased enantioselectivity for cis-1e (56% eep from cis-1e and 87% eep from 
trans-1e). The activity and selectivity of Cv-ω-TA towards cis-1e is decreased relative to the results 
observed with the chlorinated derivative (Table 1) cis-1a [with 56% eep 2e (Table 2, entry 8) relative 
to 91% eep 2a (Table 1)]. Interestingly Cv-ω-TA processes trans-1e (Table 3) with lower efficiency but 

















































































slightly higher enantioselectivity when compared to trans-1a (Table 1). With transaminase P-ω-TA, the 
selectivity for cis-1e (Table 2, entry 7) is similar to that seen with the chlorinated derivative cis-1a [with 
93% eep 2e (Table 2, entry 7) relative to 96% eep 2a (Table 1)] but intriguingly the activity is notably 
decreased for the formation of 2e (8% Ecalc) from cis-1e compared to 2a (52% Ecalc) from cis-1a. There 
is no activity observed for P-ω-TA towards trans-1e.
Clearly removing the chloro substituents has an effect on the activity and selectivity of the 
transaminases. As observed for the previous five substrates a trend is evident whereby the P-ω-TA 
exhibits selectivity toward the cis-substituted substrates relative to the trans-substituted substrates 
to a much greater extent than seen with the control transaminase Cv-ω-TA. The impact of substituents 
on the stereoselectivity patterns is very interesting with both steric and electronic effects evident; the 
effect of removal of the chloro-substituents from 1a to 1e is particularly notable.
 cis- and trans-1f (Table 2 and table 3, entries 9&10 respectively)
To investigate the effect of altered steric demand at the remote stereocentre, the phenyl ring was 
replaced with a benzyl ring (1f). For the control Cv-ω-TA the activity and selectivity for both cis-1f 
(Table 2, entry 10) and trans-1f (Table 3, entry 10) were comparable to each other and to cis- and 
trans-1a (Table 1). Transaminase P-ω-TA displayed no activity towards trans-1f with 0% conversion 
seen by 1H NMR spectroscopy, and very limited activity toward cis-1f (Table 3 and Table 2, entry 9 
respectively). Interestingly, the enantiodiscrimination in the transformation of the cis-substituted 
benzyl derivative is notably lower across both enzymes than that seen with cis-1a (Table 1) but is 
somewhat comparable to that seen with the phenyl derivative cis-1e (Table 2 entries 7&8).
 cis- and trans-1g (Table 2 and Table 3, entries 11&12respectively) 
Replacing the C-4-aryl group with a less sterically demanding methyl substituent at the C-4 position 
results in lower activity displayed by P-ω-TA towards cis-1g (Table 2, entry 11) when compared to cis-
1a (Table 1). The transaminase P-ω-TA shows low activity towards cis-1g but displays high 
enantioselectivity 93% ee for 2g (Table 2, entry 11). Notably, the trans-1g isomer is processed by P-ω-
TA with increased conversion and selectivity (Table 3, entry 11) when compared to trans-1a (Table 1). 
Evidently due to the smaller C-4-methyl substituent, both the cis and trans isomers can be 
accommodated in the active site of the enzyme although cis-1g is processed less efficiently than the 
C-4-aryl derivatives, cis-1a. Again Cv-ω-TA is very active and enantioselective for both cis-1g and trans-
1g (Table 2 and Table 3, entry 12 respectively).

















































































 cis- and trans-1h (Table 2 and Table 3, entries 13&14 respectively)
Moving the phenyl ring to the C-3-postion in 1h is a significant structural change to the substrate. This 
change allowed us to investigate if the wild-type transaminase active site could accommodate a 
phenyl substituent at this position in the way it was accommodated at the C-4 position; to the best of 
our knowledge there are currently no wild type transaminases that can accommodate such substrates. 
This structural change was not tolerated by either of the ω-transaminases, with 0% conversion across 
the screen, indicating that the active site of both enzymes (P-ω-TA and Cv-ω-TA) could not 
accommodate a C-3-aryl substituent irrespective of whether it was cis or trans to the amino 
substituent. (Table 2 and Table 3, entries 13&14 respectively). 
Substrates 1i–l illustrates the effects of substituents on the C3-position of the indane core. 
 cis- and trans-1i (Table 2 and Table 3, entries 15&16 respectively)
Moving from the tetralin core to the indane core structure, the first substrate of this series tested was 
1i, which had a phenyl ring at the C3-position on the indane moiety. P-ω-TA exhibited low activity for 
cis-1i with 4% conversion (Table 2, entry 15); when compared to cis-1e for which a percentage 
conversion of 51% (Table 2, entry 7) was achieved. The enantiopurity of the ketone formed 2i from 
cis-1i with P-ω-TA was 43% eep, lower than the enantioselectivity observed for cis-1e, the 
corresponding tetralin derivative. Notably Cv-ω-TA processed 100% of cis-1i to the ketone 2i, with no 
enantiodiscrimination, again an unusual outcome (Table 2, entry 16).
The activity of P-ω-TA towards trans-1i (Table 3, entry 15) was very low, as seen with trans-1e, and for 
the limited amounts processed, the enantioselectivity was very low. The most substantive difference 
seen between the tetralin 1e and the indane 1i was with the Cv-ω-TA, which processed trans-1e 
effectively but showed very little catalytic activity towards trans-1i. This is the only example in the 
study where Cv-ω-TA distinguished between the cis- and trans-substituted substrates, differentiating 
on the basis of the stereochemistry at the remote site; the observation of both enantiomers of cis-1i 
being processed without discrimination is notable.
 cis- and trans-1j (Table 2 and Table 3, entries 17&18 respectively)
Adding two chloro-substituents in the 3- and 4-position of the phenyl ring (1j), analogous to 1a, re-
established the remote stereoselection of cis-1j for P-ω-TA and Cv-ω-TA (Table 2, entries 17&18), 
when compared to cis-1i. This result is significant as it is clear that having the dichloro-substituted 
phenyl ring at the C-4 position of the tetralin core and at the C-3 position of the indane ring is critical 

















































































for how the substrate binds to the active site of the transaminase but becomes even more evidently 
important for the indane core structure binding capacity.
In contrast, P-ω-TA showed no activity towards trans-1j (Table 3, entry 17) and Cv-ω-TA displayed very 
low activity (8% conversion) and moderate enantioselectivity towards trans-1j (58% eep) (Table 3, 
entry 18). This result for Cv-ω-TA is notable because for trans-1a this control transaminase displays a 
high level of activity (44% conversion) and enantioselectivity (88% eep). Accordingly, while both 
enzymes display selectivity for transformation of cis-1j over trans-1j the distinction between the 
transaminase P-ω-TA and the benchmark Cv-ω-TA is less clear cut with the indane derivative than seen 
with the original sertraline amine 1a. These results indicate that both enzymes display 
enantiodiscrimination towards cis-1j over trans-1j.
 cis- and trans-1k (Table 2 and Table 3, entries 19&20 respectively) 
To further probe the effect of substituents in the indane series, a fluoro-substituent was added in the 
4-position on the C3-phenyl ring (1k). The P-ω-TA displays good activity and enantioselectivity towards 
cis-substrate-1k (amine, 84% ees) and product-2k (ketone, 82% eep), giving access to both 
enantioenriched products (Table 2, entry 19). Adding an electronegative fluorine atom to the phenyl 
ring at the C-3 position positively impacts both the activity and enantioselectivity of the transaminase 
towards cis-1k when compared to cis-1i, with the unsubstituted phenyl substituent. Having the 
fluorine atom on the phenyl ring at the C-3 position allows cis-1k to interact with the active site of P-
ω-TA and display similar conversion and enantioselectivity to that of cis-1a and cis-1j. Control 
transaminase, Cv-ω-TA displays good activity towards cis-1k (78%) with a high degree of enantiopurity 
99% ees, but poor enantioselectivity for 2k (ketone, 28% eep) . For trans-1k Cv-ω-TA displays very low 
activity with 6% conversion (Table 3, entry 20) and P-ω-TA showed no activity for the trans-substituted 
substrate 1k (Table 3, entry 19). 
Clearly the introduction of the halo-substituents on the C-3 phenyl ring enhances the efficiency of 
discrimination of cis and trans isomers in addition to the enantiodiscrimination, mirroring the trend 
seen when comparing 1a to 1e in the tetralin series.
 cis- and trans-1l (Table 2 and Table 3, entries 21&22 respectively) 
The replacement of the phenyl substituent at the C-3 position of the indane ring with a less sterically 
demanding methyl group has a significant impact on both the activity and selectivity of P-ω-TA toward 
cis-1l with an increase in activity (Table 2, entry 21) when compared to cis-1i. Clearly the smaller cis-
methyl substituent can be accommodated more easily in the active site of the enzyme. Comparing the 

















































































outcome to that seen for the analogous tetralin derivative cis-1g, it is clear that the 
enantiodiscrimination is more effective in 1g but less so in 1l highlighting the difference between the 
way in which the indane and tetralin core structures are accommodated in the active site of the 
transaminase. 
Control transaminase Cv-ω-TA displays very high level of activity for cis-1l coupled with a high degree 
of enantiopurity for the substrate cis-1l (88% ees) but poor enantiopurity for the product 2l (11% eep). 
This difference in enantiodiscrimination between the marine P-ω-TA (Table 2, entry 21) and the 
control Cv-ω-TA (Table 2, entry 22) again highlights the difference in the active sites of each enzyme.
P-ω-TA processes trans-1l with very limited activity and moderate selectivity (Table 3, entry 21). This 
result, when compared to the results for cis-1l, highlights that the remote stereodiscrimination of the 
transaminase is retained even though the enantiodiscrimination is decreased with the methyl 
substituent. 
Interestingly, variation of the C-3 substituent had a much greater impact on the enzyme activity and 
selectivity towards the indane substrates 1i–k relative to the tetralin substrates 1b–h. For the indane 
series of substrates, the marine transaminase follows a similar trend to that seen with the tetralin 
series, where it displays activity and enantioselectivity preferences towards the cis-substituted 
substrates over the trans-substituted substrates while the detailed selectivity patterns vary 
somewhat. The halogenated aryl substituents offer clear advantages both in terms of efficiency and 
stereoselectivity, perhaps related to marine origin of the transaminase.30, 56
 cis- and trans-1m (Table 2, entries 23-24 and Table 3, 23-24 respectively)
The final substrate screened was 1m, with the 6-membered ring increased to a 7-membered ring while 
retaining a phenyl substituent at the C5-position. Gratifyingly, P-ω-TA exhibited remote 
stereoselection for benzosuberan 1m with moderate activity and excellent enantioselectivity towards 
the cis-substrate (Table 2, entry 23) but no activity toward trans-1m (Table 3, entry 23), which is an 
interesting observation as benzosuberone-based natural products are an important class of medicinal 
and pharmaceutical compounds.57 For the control transaminase, Cv-ω-TA, it was seen that it could 
process both cis-1m and trans-1m with high levels of conversion 53% and 49% respectively and also 
displayed a high degree of enantioselectivity  (Table 2 and Table 3, entry 24 respectively). Once again, 
the marine transaminase demonstrates the synthetically useful discrimination of the remote 
stereocentre which is not possible with Cv-ω-TA.

















































































Conclusion for substrate scope:
Overall, the use of P-ω-TA for the deamination of a series of 1-aminotetralins and 1-aminoindanes 
indicates that this enzyme can be successfully employed across a broader substrate range compared 
to our initial study using aminotetralin 1a, leading to products with enantiopurity up to 94% ee. It is 
clear that while 4- substituents are tolerated on the tetralin core, the presence of 3- or 8- substituents 
inhibits enzyme activity. The substrate scope can be expanded to include 1-indanones and 1-
benzosuberones. In general P-ω-TA shows capacity for remote diastereoselection to a much greater 
extent than the control Cv-ω-TA, although both the stereoselectivity and efficiency is dependent on 
the precise substrate structure. Given the importance of the 1-aminotetralin and 1-aminoindane core 
structures the potential of this biocatalyst in enantioselective synthesis is clear. Interestingly, optimum 
results were obtained with 4-haloaryl 1-aminotetralin, cis-1a and 3-haloaryl 1-aminoindanes, cis-1j 
and cis-1k which may be linked to the marine origin of this enzyme. In some instances, both the ketone 













Scheme 6: Synthetic utility of P-ω-TA which yielded good enantiopurity in both recovered substrate and product
 


















































































Heterologous expression of P-ω-TA and Cv-ω-TA
Protein expression was preformed following previous protocols.35 In brief, gene specific primers were 
used to generate a gene amplicon of the transaminases, P-ω-TA and Cv-ω-TA. Directional cloning 
produced in-frame His-Tag gene fusions in the pET28a expression plasmid. Consensus gene sequence 
fidelity was analysed by sequencing the insert (Eurofins Genomics) and using the bioinformatic tool, 
Clustal Omega for local sequence alignment agreement.58 The His-Tag gene fusions in pET28a were 
introduced into the heterologous host, E. coli BL21 DE RIPL. Cells were cultured with shaking at 180 
rpm for 4 h in 37°C in LB supplemented with 50 µg/mL chloramphenicol and 50 µg/mL kanamycin. 
Following this growth phase, the plasmids were induced with 0.5 mM IPTG and incubated for a further 
4 h with shaking (180 rpm) in 23°C. Cells were pelleted using a Sorvall RC series (Thermo Scientific) at 
12,000 rpm for 10 min, maintained at a temperature of 4°C.
General Procedure for the deamination of amines
E. coli BL21 DE RIPL cells containing the expressed transaminase (30 mg) were suspended in sodium 
phosphate buffer (50 mM, pH 8.5) in a 15 mL centrifuge tube. The suspension was sonicated (30% 
intensity) using a probe for 10 s, followed by 30 s on ice. This process was repeated 5 times to lyse the 
cells. PLP solution (in 50 μL of buffer, final conc. 1 mM) and sodium pyruvate solution (in 50 μL of 
buffer, overall 1 eq.) were added, followed by the amine substrate (0.02 mmol) dissolved in 100 μL 
DMSO made up to a total volume of 1 ml, so that the final amine concentration is 20 mM. The solution 
was shaken at 30 °C, 400 rpm for 16 h. The reaction was stopped through the addition of NaOH (400 
μL, 5 M aq. solution). Ethyl acetate (≈ 4 mL) was added and the tubes were centrifuged to pellet the 
cells. The organic phase was passed through a silica plug containing Na2SO4 and the solvent was 
removed in vacuo. The crude products were analysed by 1H NMR and chiral HPLC (detailed 
methodology is provided in Supplementary Data). All experiments were replicated to ensure 
reproducibility.
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